Of the 27 peptides and peptide-adjacent compounds on this page, eight are the active ingredient of an FDA-approved product, two are in a sponsor's Phase 3 program with no approval, and the remaining seventeen have neither a US approval nor a sponsor-run US program. "Approved" applies to a specific product from a specific company, never to a research vial of the same molecule. Every row below is checked against Drugs@FDA, FDA's compounding category lists, ClinicalTrials.gov or the WADA 2026 Prohibited List, as of September 21, 2026.

What the three statuses mean

Approved means Drugs@FDA lists a product whose active ingredient is that molecule, with an application number and an approval date. The approval belongs to the product and its sponsor. A vial of the same sequence bought from a research supplier is not that product, was not made under that application, and is not covered by it.

Investigational means a company is running registered trials under an investigational new drug application and has not received an approval. The trial drug is the sponsor's material, made and released under the sponsor's controls. Research vials sold under the same name are not the trial drug.

Neither means no product in Drugs@FDA and no sponsor-run US program. Most of the molecules people search for sit here. Many of them were nominated for FDA's 503A bulks list, which is a separate question from approval and is explained in 503A, 503B and research use only.

Two columns need a note. The 503A/503B column reports FDA's interim-policy categories: Category 1 is where FDA has said it does not intend to act against compounders who meet the guidance conditions; Category 2 is where FDA has identified significant safety concerns; "withdrawn" means the nominator pulled the nomination and the substance is now in no category at all. The WADA column reports where the 2026 Prohibited List names a substance. "Not named" is not a clearance: the List's S0 class and its "similar chemical structure or similar biological effect(s)" clauses are catch-alls, which is covered in WADA S0, S2 and strict liability.

Which peptides have an FDA-approved product?

Which peptides are investigational with no approval?

A research vial labelled retatrutide is a catalog item with a sequence, a certificate and a lot number. It is not LY3437943 as made and released by its sponsor, and nothing on this site represents it as such. What investigational status means in practice is set out in retatrutide is investigational.

Which peptides have neither?

The last two rows are included because NAD+ and 5-amino-1MQ sit on peptide shelves, including ours, and are asked about in the same breath. Neither is a chain of amino acids; which of these "peptides" are peptides explains both, and glutathione beside them.

What "withdrawn" means, and what it does not

Nine of the rows above changed on April 22, 2026, when FDA's Category 2 page moved twelve peptides to a section headed "nominated but withdrawn": a procedural event, not a safety finding, that leaves each substance in no category and off the 503A bulks list. The full sequence, including the July 2026 advisory committee meeting at which FDA staff proposed that seven of them not be listed, is in Category 1, Category 2 and the 503A bulks list, and the most-searched case is in BPC-157 in 2026.

Why an approved product and a research vial are not the same thing

Approval attaches to an application: a named sponsor, a manufacturing process, a specification, a label. Geref's approval from 1997 belongs to EMD Serono's product, and that product is discontinued. It says nothing about a vial of sermorelin sold as a research reagent, which is what we stock. The same is true of Vyleesi and a research vial of bremelanotide, and of Forzinity and a vial labelled SS-31.

This cuts the other way too. FDA's August 2026 warning letters cite sellers of research "Tesamorelin," "PT-141" and "SS-31" for marketing unapproved new drugs, even though an approved product with the same active ingredient exists. What made the research product a drug in FDA's reading was the seller's own text, which is the subject of what FDA reads before calling a research product a drug.

Reading the table

Use the first column to find the molecule, then read across. If the "approved product" cell names a product, that product is the only form of the molecule with an FDA approval. If the 503A/503B cell says "withdrawn" or "Category 2," no pharmacy pathway under section 503A exists for it today. If the WADA cell names a section, the substance is prohibited in sport at all times regardless of its FDA status. The full catalog, with each item's identity data, is at the catalog.

Sources

• Drugs@FDA: Ozempic, NDA 209637, FDA
• Drugs@FDA: Mounjaro, NDA 215866, FDA
• Drugs@FDA: Victoza, NDA 022341, FDA
• Drugs@FDA: Geref, NDA 020443, FDA
• Drugs@FDA: Egrifta, BLA 022505, FDA
• Drugs@FDA: Vyleesi, NDA 210557, FDA
• Drugs@FDA: Scenesse, NDA 210797, FDA
• Drugs@FDA: Forzinity, NDA 215244, FDA
• Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA, content current April 22, 2026
• Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (PDF), FDA, updated May 14, 2026
• FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, FDA, content current April 1, 2026
• 503B bulk drug substance categories (PDF), FDA, updated March 21, 2025
• ClinicalTrials.gov API v2 query for GHK-Cu, National Library of Medicine, queried September 21, 2026
• The 2026 Prohibited List (PDF), World Anti-Doping Agency, valid January 1, 2026